LOXO - upgraded at MS

Loxo Oncology upgraded to Overweight after competitor data at Morgan Stanley As previously reported, Morgan Stanley analyst Matthew Harrison upgraded Loxo Oncology (LOXO) to Overweight from Equal Weight after competitor Blueprint Medicines (BPMC) provided initial data at the AACR meeting on its RET inhibitor BLU-667 that he believes was at the lower-end of Loxo investors' expectations from a competition standpoint. He now believes Loxo has an opportunity to demonstrate differentiation on both efficacy and safety for LOXO-292 versus BLU-667 when updated data are presented at the ASCO meeting in June. Harrison, who sees the most opportunity for LOXO-292 being a better adverse effect profile, raised his price target on Loxo shares to $170 from $130. LOXO is licensed from ARRY

Also from Stifel - Blueprint data leaves 'door wide open' for LOXO-292.